JPRN-UMIN000004359
Recruiting
N/A
A Phase I/II Trial of combined adjuvant therapy with gemcitabine and cisplatin for resected biliary tract cancer - A Phase I/II Trial of combined adjuvant therapy with gemcitabine and cisplatin for resected biliary tract cancer
Shinshu University School of Medicine, Surgery0 sites33 target enrollmentNovember 1, 2010
ConditionsResected biliary tract cancer
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Resected biliary tract cancer
- Sponsor
- Shinshu University School of Medicine, Surgery
- Enrollment
- 33
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •Interstitial pneumonia heart failure ascites and edema Infection diabetes mellitus Allergy of the drugs
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 1
A phase I clinical trial on combined (neo-)adjuvant intravenous plus intracranial administration of ipilimumab and nivolumab in recurrent glioblastoma.glioblastomaMedDRA version: 20.0Level: PTClassification code: 10018337Term: Glioblastoma multiforme Class: 100000004864MedDRA version: 20.0Level: PTClassification code: 10018336Term: Glioblastoma Class: 100000004864Therapeutic area: Diseases [C] - Neoplasms [C04]CTIS2023-508278-26-01Z Brussel18
Completed
N/A
The phase I/II study of the adjuvant therapy using alpha-galactosylceramide pulsed dendritic cells for patients with advanced high-grade salivary gland tumor followed by standard therpies.Salivary gland tumorJPRN-UMIN000024669Chiba University Hospital6
Completed
Phase 1
The phase I/II study of the adjuvant therapy using alpha-galactosylceramide pulsed antigen presenting cells for patients with high-grade salivary grand tumor followed by standard therpies.High-grade salivary grand tumorJPRN-UMIN000011509Department of Otorynolaryngology, Head and Neck Surgery, Graduate School of Medicine, Chiba University9
Completed
Phase 3
A phase III randomized trial of adjuvant therapy with irsogladine maleate for the patient with completely resected non-small cell lung cancernon-small cell lung cancerJPRN-UMIN000005901Japanese Northern East Area Thoracic Surgery Study Group (JNETS)310
Active, Not Recruiting
N/A
Phase II trial assessing neoadjuvant therapy with FEC 100 followed by Taxotere® (docetaxel) plus Vectibix® (panitumumab) in patients with operable, HR and Her-2 negative breast cancer. TVA study. - TVA studyRH- and Her2- operable breast cancer, in neoadjuvant situationMedDRA version: 9.1Level: LLTClassification code 10022882Term: Invasive ductal breast cancerEUCTR2009-012853-39-FRCentre Jean Perrin